Publications by authors named "H X Y Yeoh"
Background: Connexins (Cx) 43 and 40 play a role in leukocytes recruitment in acute inflammation. They are expressed in the endothelial cells. They are also found in the placenta and involved in the placenta development.
View Article and Find Full Text PDFArticle Synopsis
- Anti-PD-1 antibodies and BRAF/MEK inhibitors can help reduce recurrence risk in resected stage III melanoma patients, and the study investigated the effectiveness of a 'second adjuvant' BRAF/MEKi therapy for those who experienced recurrence after initial treatment.
- A total of 73 BRAFmut melanoma patients were analyzed, with 61 receiving 'second adjuvant' therapy and showing significant improvements in recurrence-free survival (RFS) compared to those who didn’t receive this treatment.
- While the second adjuvant therapy led to better RFS, it also resulted in high rates of toxicity, prompting a need for further research on treatment strategies to enhance outcomes while minimizing side effects.
Introduction: Hydatidiform mole is one of the gestational trophoblastic disease and comprises complete (CM) and partial moles (PM), which carries a risk of developing persistence disease, invasive mole or choriocarcinoma. MicroRNAs (miRNAs) have been discovered in various tissues, including neoplastic tissues. Its role in the pathogenesis of molar pregnancy or as biomarkers are still largely uncertain.
View Article and Find Full Text PDFThis study assessed the association between COVID-19 vaccines, SARS-CoV-2 infection and the risk of thrombocytopenia and venous thromboembolism (VTE). This self-controlled case series study used hospital records between 1st February 2021 and 28th February 2022 linked to the national immunisation registry and COVID-19 surveillance data in Malaysia. Conditional Poisson regression was used to estimate incidence rate ratios (IRR) of events in the risk period (day 1-21 post-exposure) relative to control period with the corresponding 95% confidence interval (CI) adjusted for calendar period.
View Article and Find Full Text PDFImportance: Anti-programmable cell death-1 (anti-PD-1) improves relapse-free survival when used as adjuvant therapy for high-risk resected melanoma. However, it can lead to immune-related adverse events (irAEs), which become chronic in approximately 40% of patients with high-risk melanoma treated with adjuvant anti-PD-1.
Objective: To determine the incidence, characteristics, and long-term outcomes of chronic irAEs from adjuvant anti-PD-1 therapy.